Belly Fat, Not BMI, May Raise Lung Cancer Risk by Silencing Airway Immunity

For years, researchers studying lung cancer have wrestled with a puzzling contradiction. Obesity is well established as a driver of at least thirteen cancer types, yet several large epidemiological analyses suggested that people with lung cancer were, if anything, less likely to be obese than their cancer-free counterparts. This counterintuitive pattern became known as the obesity paradox, and it has lingered in the literature as one of the more uncomfortable loose ends in cancer epidemiology. A new study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer, argues that the paradox may be an artifact of how obesity has been measured all along, and that the true relationship between body fat and lung cancer is not protective at all but dangerously permissive.

The research, led by Joseph Barbi, PhD, and Sai Yendamuri, MD, MBA, FACS, of Roswell Park Comprehensive Cancer Center in Buffalo, New York, began with a simple but consequential methodological decision. Rather than relying on body mass index, the team analyzed computed tomography scans and clinical information from 1,170 individuals at high risk for lung cancer, including 594 patients with early-stage disease and 576 individuals without lung cancer. CT imaging allowed the investigators to quantify total abdominal fat area directly, capturing the actual volume and distribution of fatty tissue rather than the crude height-to-weight ratio that BMI provides. The distinction proved decisive. Patients with lung cancer had significantly greater total abdominal fat area than controls, while their BMI values were statistically indistinguishable.

The numbers illustrate the point vividly. Median total abdominal fat area measured 300.7 square centimeters among the lung cancer patients compared with 267 square centimeters among controls, a difference that reached statistical significance at p equal to 0.006. Median BMI, by contrast, was 26.9 kilograms per square meter in the cancer group and 26.4 among controls, a gap far too small to carry any statistical weight. After the researchers adjusted for confounding variables including age, sex, and smoking status, abdominal fat remained significantly associated with the presence of lung cancer. Even among participants with elevated BMI, those with lung cancer carried significantly more abdominal fat than individuals in the screening cohort, suggesting that fat distribution, not overall body size, is what matters.

This finding strikes at a long-recognized weakness in the way obesity science has been conducted. BMI cannot distinguish muscle from fat, nor can it reveal where fat is deposited in the body. Visceral adipose tissue, the fat that wraps around abdominal organs, is metabolically distinct from subcutaneous fat stored under the skin. It secretes a different profile of inflammatory cytokines, adipokines, and signaling molecules, and it is the depot most consistently linked to insulin resistance, chronic low-grade inflammation, and now, according to this study, lung cancer risk. Studies that relied exclusively on BMI may have systematically misclassified patients whose central adiposity was masked by a normal or low overall body weight, a scenario particularly relevant to lung cancer populations, in which smoking-related metabolic changes and muscle wasting can distort weight-based measures.

But the Roswell Park team did not stop at epidemiology. To probe whether abdominal fat might do more than merely correlate with lung cancer, the investigators turned to airway gene-expression data from additional patients. The analysis revealed that greater adiposity was associated with suppression of immune pathways that normally help the body identify and eliminate malignant cells. This observation reframed the question entirely. If excess fat does not simply coexist with lung tumors but actively reshapes the immunological landscape of the airways, then obesity could be functioning as an accomplice to carcinogenesis, quietly disarming the sentinels that would otherwise destroy emerging cancer cells before they gain a foothold.

To test that hypothesis under controlled conditions, the researchers compared normal-weight mice with mice made obese on a high-fat diet. The obese animals exhibited significant remodeling of the immune environment within their lungs. Populations of regulatory T cells, the immunological brakes that restrain immune responses, expanded markedly, as did potentially suppressive myeloid cells, a heterogeneous family of innate immune cells that can inhibit antitumor activity. At the same time, the mice showed evidence of impaired effector T cell activity, meaning the cytotoxic forces responsible for killing infected and malignant cells were functioning at reduced capacity. The net effect was an airway environment tilted away from immune surveillance and toward immune tolerance of abnormal cells.

The team then pushed the experiment further, using both genetically driven and chemically induced models of lung carcinogenesis. In these systems, obesity significantly increased lung tumor development, providing direct causal evidence rather than mere correlation. Because the models allowed the investigators to track immune-cell populations as tumors emerged and progressed, they could observe the sequence of events: fat accumulation first, then immune suppression, then tumor outgrowth. The data support the interpretation that obesity impairs the lung’s ability to eliminate newly emerging malignant cells at the earliest stages of transformation, when intervention is most effective and before a tumor has had the chance to establish an immunosuppressive microenvironment of its own.

Two additional lines of evidence strengthened the mechanistic case. First, when the researchers isolated regulatory T cells from the lungs of obese mice and tested them in vitro, those cells proved significantly more effective at suppressing the proliferation of responder T cells than regulatory T cells harvested from normal-weight animals. The suppressive machinery of these cells was not merely more abundant but functionally enhanced, a qualitative change that could meaningfully blunt antitumor immunity. Second, and critically for translational relevance, cellular analysis of bronchoalveolar lavage samples from 109 human patients confirmed that several of the obesity-associated immune changes observed in mice are also present in the human airway in the setting of high adiposity. The animal findings, in other words, are not laboratory curiosities but reflections of biology operating in real patients.

Taken together, the results suggest a coherent biological narrative. Excess adiposity, particularly central fat, appears to alter the immune environment of the airway in ways that favor both the initiation and the persistence of lung tumors. Regulatory T cells and suppressive myeloid cells accumulate, effector T cell function wanes, and the immune system’s capacity for surveillance of early malignant cells erodes. Dr. Barbi summarized the conclusion in the study, writing that the data clearly associate central adiposity with heightened lung cancer risk and strongly implicate increased immune-suppressing mechanisms in the airways of obese mice and patients as a potential contributing factor. The authors conclude that obesity is associated with enhanced lung carcinogenesis and that immune-suppressive mechanisms tied to excess fat, including activated regulatory T cells, are evident in both clinical and preclinical systems.

The implications extend well beyond settling a scholarly dispute. The findings reconcile the apparent contradiction between BMI-based epidemiological studies and the extensive body of evidence showing that obesity impairs antitumor immunity, resolving what had seemed like a paradox into a measurement problem compounded by biology. More practically, they point toward intervention. If specific immune-suppressive mechanisms in the airway can be identified and characterized, as this study begins to do, then ongoing efforts aimed at reversing those effects with existing or novel therapies may offer a means of combating lung cancer development in people who are overweight or obese, populations that continue to grow across much of the world. For a disease that remains the leading cause of cancer death globally, any strategy that strengthens immune surveillance before tumors take hold represents a potentially significant addition to the prevention toolkit, and this study provides both the epidemiological justification and the mechanistic roadmap for pursuing it.

Subject of Research: The association between abdominal adiposity and lung cancer risk through obesity-induced airway immune suppression

Article Title: New study challenges “obesity paradox” in lung cancer, points to suppressed airway immunity

Article References: New study challenges “obesity paradox” in lung cancer, points to suppressed airway immunity. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: lung cancer, obesity, adiposity, body mass index, regulatory T cells, immune surveillance, myeloid cells, abdominal fat, Journal of Thoracic Oncology, carcinogenesis, airway immunity, immunosuppression